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Background: The role of urine markers in the surveillance of patients with non-muscle invasive bladder cancer
(NMIBC) is discussed extensively. In case of negative cystoscopy the additional prognostic value of these markers
has not been clearly defined yet. The present study is the first systematic approach to directly compare the ability
of a urine marker panel to predict the risk of recurrence and progression in bladder cancer (BC) patients with no
evidence of relapse during surveillance for NMIBC.
Methods: One hundred fourteen patients who underwent urine marker testing during surveillance for NMIBC and
who had no evidence of BC recurrence were included. For all patients cytology, Fluorescence-in-situ-hybridization
(FISH), immunocytology (uCyt+) and Nuclear matrix protein 22 enzyme-linked immunosorbent assay (NMP22) were
performed. All patients completed at least 24 months of endoscopic and clinical follow-up of after inclusion.
Results: Within 24 months of follow-up, 38 (33.0%) patients experienced disease recurrence and 11 (9.8%) progression.
Recurrence rates in patients with positive vs. negative cytology, FISH, uCyt+ and NMP22 were 52.6% vs. 21.9%
(HR = 3.9; 95% CI 1.75-9.2; p < 0.001), 47.6% vs. 25.0% (HR 2.7; 1.2-6.2; p = 0.01), 43.8% vs. 22.4% (HR 3.3; 1.5-7.6; p = 0.003)
and 43.8% vs. 16.7% (HR 4.2; 1.7-10.8; p = 0.001). In patients with negative cytology, a positive NMP22 test was
associated with a shorter time to recurrence (p = 0.01), whereas FISH or uCyt+ were not predictive of recurrence in
these patients. In the group of patients with negative cytology and negative NMP22, only 13.5% and 5.4% developed
recurrence and progression after 24 months.
Conclusions: Patients with positive urine markers at time of negative cystoscopy are at increased risk of recurrence
and progression. In patients with negative cytology, only NMP22 is predictive for recurrence. Patients with negative
marker combinations including NMP22 harbour a low risk of recurrence. Therefore, the endoscopic follow-up regimen
may be attenuated in this group of patients.
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Patients with non-muscle invasive bladder cancer (NMIBC)
harbour a significant risk of tumor recurrence and pro-
gression [1]. Several risk stratifications have been devel-
oped to predict the risk of recurrence or progression
based on clinical and pathologic parameters [2]. However,
these tools have only limited value in predicting the pa-
tients’ individual risk. Therefore, improved risk stratifica-
tion is urgently needed. Due to the lack of reliable tools
for prognosis of patients with NMIBC, the optimal follow-
up of these patients is discussed controversially. White
light cystoscopy remains the gold standard for surveillance
of patients after NMIBC. The main limitations of cystos-
copy are its limited sensitivity for flat lesions and its char-
acter as an invasive procedure potentially leading to
significant discomfort for the patients [3,4]. Urine cytology
is also recommended as standard in the follow-up of pa-
tients with NMIBC, as it is a non-invasive procedure with
the potential to detect flat lesions not visible in cystoscopy
[5]. However, its sensitivity is satisfactory only for high
grade tumors or carcinoma in situ. Newer markers such
as fluorescence-in-situ hybridization (FISH), immunocy-
tology (uCyt+) or Nuclear matrix protein 22 (NMP22)
have shown increased sensitivitity compared to cytology
[6,7]. However, their specificity has been reported to be
lower compared to cytology in most studies. For some of
these markers, particularly the UroVysion FISH test previ-
ous studies have shown that a positive marker might pre-
cede visual or histologic detection of a tumor recurrence.
Hence, some tests may be capable of detecting molecular
changes associated with tumor recurrence earlier than
cystoscopy [8,9]. The clinical implications and the optimal
management of these patients with negative cystoscopy or
biopsy and concomitantly positive markers remain to be
defined.
To date only few data exist on the predictive values of
multiple urine markers in this negative-cystoscopy set-
ting. The present study is the first to address this issue
concerning the four most widely available urine markers
(Cytology, FISH, uCyt + and NMP22).
Methods
Patients and samples
114 patients (95 men and 19 women, median age 70,
range 40-96) undergoing surveillance of NMIBC were
enrolled. All patients had a negative cystocopy or, in case
of suspicious findings, a negative histology at time of
inclusion. Collection of urine samples was performed
directly before cystoscopy. Upper tract imaging was per-
formed in patients with positive cytology and/or FISH.
In patients with suspicious or inconclusive findings in
upper tract imaging, retrograde ureterorenoscopy was
performed (n = 14, all negative). In patients with cytology
highly suspicious for urothelial carcinoma (correspondingto categories IV + V of the Papanicolaou classification sys-
tem), mapping biopsies were performed within four weeks
of urine sampling (n = 9, all negative). Median time be-
tween last evidence of tumor and urine sampling & cyst-
oscopy was six months (3-48). Written informed consent
was obtained from all patients. The study was approved
by the local ethics committee (Ethikkommission der Uni-
versität Tübingen, No. 400/2009A).
Urine tests and diagnostic criteria
Urine samples of all patients were analyzed by cytology,
FISH, uCyt + and NMP22). For cytology, Papanicoulaou
staining was performed. Microscopic assessment was done
according to the recommendations of the Papanicolaou
Society of cytopathology [10]. The following features were
assessed to identify malignant cells: papillary clusters of
cells with eccentric nuclei, single cells with eccentric nu-
clei, an increased nuclear-to-cytoplasma ratio, irregular
nuclear borders and coarse chromatin. Atypical urothelial
cells and urothelial carcinoma cells (corresponding to cat-
egories III-V of the Papanicolaou classifiction system)
were considered positive [11,12].
The UroVysion FISH assay was performed as previously
described [13]. The following chromosomal patterns were
required for a positive test: ≥4 out of 25 morphologically
suspicious cells with ≥3 signals of at least two chromo-
somes 3, 7, 17 or ≥12 nuclei with homozygous loss of
9p21 [14]. Immunocytology (uCyt+) was preformed as de-
scribed previously. The test was stated positive, if ≥1 cells
show a clear (granulated) positive immunofluorescence
signal of CEA or Mucin [15]. The NMP22 enzyme-linked
immuno sorbet assay (ELISA) was performed according
to the recommendations of the manufacturer and consid-
ered positive for values ≥10 IU/ml [16].
All patients underwent cystoscopy and biopsy or
transurethral resection case of positive findings. Patients
were considered positive for tumor if at least one suspi-
cous area was observed during cystoscopy and malig-
nancy was confirmed by subsequent histopathology.
Follow-up
For all patients, an in-house cystoscopic follow-up of at
least 24 months after urine sampling was available. Pa-
tients were followed up according to the recommenda-
tions of the European Association of Urology [1].
Recurrence was defined as histologically proven bladder
cancer of any grade and stage within the follow-up of
24 months. Progression was defined as any increase in
tumor stage or grade. Urine marker results obtained at
later time points were not included into analysis.
Statistics
Kaplan-Meier-curves were used to estimate times to re-
currence and progression in patients with and without
Table 1 Patients’ characteristics
Total number of patients, n 114
Age, years, Median (Range) 70 (40-96)
Gender, male/female 95/19
Recurrence within 24 months, n (%) 38 (33.0)
pT Stage of first recurrence within 24 months
pTa 25 (65.8)
pT1 5 (13.1)
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univariate and multivariate Cox proportional hazard
analyses were used to compare the risk of recurrence
and progression in patients with and without positive
marker(s). P-values ≤ 0.05 were considered significant.
To compare rates of recurrence and progression be-
tween patients with different numbers of markers in a
combination positive, the Cochrane Armitage test for





Interval between last bladder cancer episode and
urine marker sampling, months, Median (Range)
6 (3-84)
pT/Grade last bladder cancer episode before urineResults
Patients’ characteristics are summarized in Table 1. During
the follow-up of 24 months, 38 (33.0%) patients experi-
enced disease relapse. The median time to recurrence was
11.5 months (3-24). 12 patients (10.5%) experienced dis-
ease progression during follow-up. Median time to pro-
gression was 11 months (3-24).marker sampling, n (%)
pTa 74 (64.9)
pT1 28 (24.5)
Cis (pure) 12 (10.5)
Cis (concomitant) 11 (9.6)Urine marker results
At the time of urine marker sampling cytology, FISH,
uCyt+ and NMP22 ELISA were positive in 39 (34.2%), 42
(36.8%), 66 (57.8%) and 66 (57.8%) patients, respectively.G1 51 (44.7)
G2 35 (30.1)
G3 16 (14.0)
Highest pT/Grade in patient’s history before urine
marker sampling, n (%)
pTa 71 (62.3)
pT1 32 (27.3)
Cis (pure) 11 (9.6)




Time to recurrence, months, Median (Range) 12.5 (3-24)
Patients developing progression, n (%) 13 (11.4)
Time to progression, months, Median (Range) 11 (3-24)
Cis = carcinoma in situ.Correlation of single urine markers with recurrence and
progression
Rates of recurrence and progression and after 12 and
24 months in patients with negative and positive cy-
tology, FISH, uCyt+ and NMP22 are summarized in
Tables 2 and 3. Hazard ratios for recurrence and pro-
gression for patients with positive and negative markers
are shown in Tables 2 and 3. Kaplan Meier analysis
for recurrence and progression in patients with negative
and positive markers are shown in Figure 1A-D. Single
positive markers were associated with an increased
risk for both recurrence and progression within 12 and
24 months. No significant differences were observed for
rates of recurrences after 12 months in patients with
negative and positive FISH and for rates of progression
after 2 years in patients with negative and positive
NMP22.
As some of the recurrences detected in the first
12 months after initial cystoscopy might present no ac-
tual recurrences but tumors missed by initial cystoscopy,
the role of urine markers to predict recurrence was
determined separately for recurrences occurring later
than one year after initial cystoscopy. Rates of recur-
rences and progression occurring between month 12-
24 are shown in Table 4. Results of single markers
remained predictive even for recurrences occurring
later than 12 months whereas progression between
month 12 and 24 only correlated with the results of
cytology.Anticipatory positive urine marker combinations
As cytology is the test most commonly used for surveil-
lance of BC patients, we evaluated whether in patients
with negative cytology, the results of other markers in-
fluence the risk of recurrence. Kaplan-Meier Analysis
for patients with negative cytology and negative or posi-
tive FISH, uCyt+ and NMP22 are shown in Figure 1E-G.
Recurrence free survival was significantly shorter for pa-
tients with positive vs. negative NMP22 at initial assess-
ment (Figure 1G).
Table 2 Prediction of recurrence by single urine markers in case of negative cystoscopy in the follow up of non muscle
invasive bladder cancer
Urine marker Result n Rate of tumor recurrence
in % (after 12 months)
Hazard ratio p-value Rate of tumor recurrence
in % (after 24 months)
Hazard ratio p-value
Cytology - 75 9.3 4.3 (1.6-12.7) .004 21.9 3.9 (1.75-9.2) <.001
+ 39 30.7 52.6
FISH - 72 12.5 2.2 (0.8-6.0) .12 25.0 3.3 (1.5-7.6) .01
+ 42 23.8 47.6
uCyt+ - 67 10.5 2.93 (1.2-8.0). .03 22.4 2.7 (1.2-6.2) .003
+ 66 25.5 43.8
NMP22 - 48 6.3 4.79 (1.47-21.6) .007 16.7 4.2 (1.7-10.8) .001
+ 66 24.4 43.8
FISH = Fluorescence in situ hybridization, uCyt + = Immunocytology, NMP22 = Nuclear matrix protein 22.
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eously, the risk of recurrence and progression may be in-
fluenced by the number of tests positive in a combination
of two, three or four markers. Rates of recurrence and
progression in patients with differing numbers of positive
tests in 2-,3- or 4-test combinations are summarized in
Table 5. The number of positive tests in the combinations
was significantly associated both with recurrence and
progression In patients having no marker positive in
2-test-combinations including NMP22, the rates of recur-
rence after 2 years were as low as 13.5% (NMP22 & cy-
tology), 11.1% (NMP22 & FISH) and 9.4% (NMP22 &
immunocytology). However, the proportion of patients
with both tests negative in these combinations were only
between 28.1% and 31.6%.
Rates of recurrence and progression in patients with
all urine tests positive vs. those with all tests negative
were 81.3% vs. 11.5% (HR 33.2, 6.8-233.1, p < 0.001) and
43.8% vs. 3.8% (HR 19.4, 2.9-390.7, p = 0.001).
Multivariable analysis
The risk of recurrence may be strongly influenced by
other factors such as risk groups defined by the EAU [1].
As patients were included at different time points ofTable 3 Prediction of progression by single urine markers in
muscle invasive bladder cancer
Test Result n Rate of tumor progression
in % (12 months)
Hazard ratio
Cytology - 75 1.3 11.6 (1.7-226.1)
+ 39 13.5
FISH - 72 1.4 9.72 (1.5-189.9)
+ 42 12.2
uCyt+ - 67 1.5 8.3 (1.3-161.0)
+ 66 11.1
NMP22 - 48 0 28×106(2.04-n.a
+ 66 9.2
FISH = Fluorescence in situ hybridization, uCyt + = Immunocytology, NMP22 = Nuclefollow-up, time interval between last tumor (proven by
histopathology) and inclusion into the study might also
strongly affect the results. Multivariate analyses control-
ling for results of cytology, interval between last tumor
and inclusion into the study and risk groups (according
to the guidelines of the EAU [1]) are shown in Table 6.
Discussion
The use of urine markers in the surveillance of patients
with NMIBC has increased significantly in the last dec-
ade, although current guidelines give clear recommenda-
tions only for cytology. Urine markers are considered to
be a valuable adjunct to cystoscopy [17,18]. However,
the optimal work-up of patients with negative cystos-
copy and positive urine markers - particularly for newer
markers with decreased specificity compared to cytology
- has not been clearly defined yet. It has been frequently
discussed whether the presence of a positive marker in
the absence of obvious changes in the bladder mucosa
may indicate the presence of a non-visible tumor. Others
even consider predicting the development of a tumor in
the near future. Several reports indicate that anticipatory
positive urine markers may indeed precede clinical tumor
recurrence. The phenomenon of anticipatory positivecase of negative cystoscopy in the follow up of non
p-value Rate of tumor progression
in % (24 months)
Hazard ratio p-value
.008 4.0 7.2 (2.0-34.2) <.001
23.1
.01 4.2 6.2 (1.7-29.7) .004
21.4
.025 4.5 5.1 (1.4-23.8) .01
19.2
.) .009 6.2 2.4 (0.7-11.1) .19
13.6
ar matrix protein 22.
Figure 1 Recurrence free survival in patients showing negative follow-up cystoscopy after nonmuscle invasive bladder cancer and
single tests positive and negative for the whole cohort (A-D) and patients with negative cytology (E-G). FISH = Fluorescence in situ
hybridization, NMP22 = Nuclear matrix protein 22, uCyt + = Immunocytology.
Todenhöfer et al. BMC Cancer  (2015) 15:155 Page 5 of 11markers has been firstly described by Steiner et al, who
assessed the feasibility of microsatellite analysis in the fol-
low up of 21 patients with NMIBC. In their cohort, two
patients were positive for urine microsatellite analysis four
and six months prior to cystoscopic detection of tumors[19]. A comparison of multiple urine markers and their
combination has not been performed yet with regards to
their anticipatory role. The aim of the present study was
to compare the oncologic outcomes of patients with posi-
tive and negative cytology, FISH, uCyt+ and NMP22 at
Table 4 Prediction of recurrence and progression occurring between month 12-24 after urine sampling
Test Result n Rate of tumor recurrence
in % (between month 12-24)
Hazard ratio p-value Rate of tumor progression
in % (between month 12-24)
Hazard ratio p-value
Cytology - 68 14.7 2.89 (1.1-8.3) .04 2.9 5.7 (1.1-43.4) .04
+ 27 33.3 14.8
FISH - 63 14.3 2.72 (1.0-7.8) .05 3.2 4.35 (0.8-32.8) .08
+ 32 31.3 12.5
uCyt+ - 60 13.3 2.9 (1.1-8.6) .03 3.3 3.7 (0.7-28.1 .12
+ 35 31.4 11.4
NMP22 - 45 11.1 3.1 (1.1-10.4 .03 6.7 1.11 (0.2-6.3) .89
+ 50 28.0 6.0
FISH = Fluorescence in situ hybridization, uCyt + = Immunocytology, NMP22 = Nuclear matrix protein 22.
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sess the impact of these markers on recurrence and pro-
gression when used in combinations.
In univariable analysis we observed for all markers to
be highly predictive for recurrence and progression. Of
note, patients with positive markers were at higher risk
for recurrence even 1-2 years after urine marker testing
and negative cystoscopy. This implies, that the tests
might be able to display premalignant changes that are
not visible macroscopically. Interestingly, in the group of
patients having negative cytology, the only marker that
was associated with increased risk of recurrence was
NMP22. This indicates that both FISH and immunocy-
tology markedly overlapped with cytology with regards
to prediction. When combining urine markers, we ob-
served that the more markers are positive in different
combinations, the higher is the risk for recurrence
and progression. For various combinations including
NMP22, the risk of having disease recurrence and pro-
gression within 24 months was as low as 9.5-13.5% and
2.8-5.4% for patients with both tests negative (depend-
ing on the combination). Of note, a negative 4-test
combination was not associated with a further decrease
in the probability of recurrence and progression com-
pared to the 2-test-combination with the highest nega-
tive predictive value (when considering recurrence as an
event). Therefore, the use of more than two markers
does not seem to provide additional benefit with regards
to prediction of outcome.
The observation, that positive urine markers may pre-
cede visible tumor recurrence is in accordance with pre-
vious studies. In a cohort of 1114 patients tested by
urine cytology, the anticipatory positive rate of cytology
was 44% after a median time of 15 months [9]. Com-
pared to our study, the rate of patients having a positive
cytology but no positive histology within one year of
follow-up was clearly lower. This finding may be related
to the fact that cytology is strongly dependant on the cy-
topathologist [20].UroVysion FISH has been observed to be positive be-
fore visible tumor recurrence in various studies. In a
study by Yoder et al., 56 of 250 patients with atypical or
negative cytology were positive for FISH and had no vis-
ible tumor recurrence at initial cystoscopy. In 35 of these
patients (62.5%), tumor recurrence developed during the
median follow-up of 23 months. Similar results were ob-
served in a study including 68 patients under surveillance
for NMIBC having negative cytology and cystoscopy at
time of inclusion. During the median follow-up of
13.5 months, 45% of patients with positive UroVysion de-
veloped recurrence vs. 12.5% with normal UroVysion test.
The proportion of patients with positive UroVysion at
time of inclusion was considerably high (62.5%), given the
fact that all were negative for cystoscopy at time of testing
[21]. These findings are in contrast to our study, where in
the group of patients with negative cytology, the rates of
recurrence did not differ significantly between FISH posi-
tive and negative patients. This might be also caused by
other criteria used for positive cytology. In a study from
Italy 75 patients during follow-up of NMIBC were divided
into patients with low molecular grade (changes in 9p21
or chromosome 3) and high-molecular grade (gains of
chromosome 7 or 17) FISH results. Those patients with
high molecular grade had a significantly shorter time to
recurrence. In this study, no substratification was per-
formed for cytology positive and negative patients [22].
However, the criteria used in this study were different
compared to ours. It is broadly accepted that the inter-
pretation criteria might strongly influence the prognostic
value of UroVysion results. In a study including 138 pa-
tients with negative cystoscopy during follow-up for
NMIBC, the UroVysion criteria proposed by the manufac-
turer were not predictive for recurrence. In contrast, cri-
teria based on previous evidence suggesting that rare
tetraploidic cells have a less strong diagnostic value than
other aberrations, showed a significant association with
disease recurrence [23,24]. Another test based on detec-
tion of genomic alterations which has been demonstrated




























(0 vs. 1 vs. 2)
2-test-combinations Cytology & FISH 0 62 9.7 .01 1.6 .004 22.6 .001 3.3 <.001
1 23 17.4 0 30.4 8.7
2 29 31.0 17.2 58.6 28.6
Cytology & uCyt+ 0 53 9.4 .002 1.8 .003 20.8 <.001 3.8 <.001
1 36 11.1 0 27.8 5.6
2 25 40.0 20.0 68.0 32.0
Cytology & NMP22 0 37 2.7 .004 0 .002 13.5 <.001 5.4 .004
1 49 16.3 2.0 30.6 4.1
2 28 35.7 17.9 64.3 28.6
FISH & uCyt+ 0 50 12.0 .02 2.0 .004 24.0 <.001 6.0 <.001
1 39 10.3 0 23.1 0
2 25 36.0 20.0 68.0 36.0
FISH & NMP22 0 36 2.8 .008 0 .003 11.1 <.001 2.8 <.001
1 48 20.8 2.1 37.5 8.3
2 30 26.7 16.7 53.3 23.3
uCyt + & NMP22 0 32 0 .001 0 .004 9.4 <.001 3.1 <.001
1 51 19.6 1.9 33.3 7.8
2 31 29.0 16.1 58.1 22.6
3-test-combinations Cytology & FISH
& uCYt
0 44 11.4 <.001 2.3 .001 22.7 <.001 4.6 <.001
1 33 6.1 0 21.2 3.0
2 16 25.0 0 37.5 6.25
3 21 38.1 23.8 71.4 38.1
Cytology & FISH
& NMP22
0 33 0 .001 0 .001 9.1 <.001 3.0 <.001
1 36 22.2 2.8 38.9 5.6
2 24 12.5 0 25.0 8.3











Table 5 Risk of recurrence and progression according to the number of urine markers positive in 2-, 3-, and 4-marker combinations (Continued)
Cytology & uCyt +
& NMP22
0 37 2.7 <.001 0 .002 13.5 <.001 5.4 <.001
1 38 15.8 2.6 31.6 2.6
2 11 18.2 0 27.3 9.1
3 28 35.7 17.8 64.3 28.6
FISH & uCyt +
& NMP22
0 27 0 .002 0 .001 11.1 <.001 3.7 <.001
1 37 18.9 2.7 27.0 5.4
2 32 15.6 0 37.5 6.25
3 18 38.9 27.8 72.2 38.9
4-test-combination Cytology & FISH &
uCyt + & NMP22
0 26 0 <.001 0 <.001 11.5 <.001 3.9 <.001
1 28 17.9 3.6 25.0 3.6
2 30 13.3 0 33.3 6.7
3 14 21.4 0 35.7 7.2
4 16 43.8 31.3 81.3 43.8











Table 6 Mulitvariate analysis for prediction of recurrence adjusted for results of cytology, time interval between last









Hazard ratio p Hazard ratio p Hazard ratio p Hazard ratio p
Cytology 2.8 (1.2-7.0) .02 2.2 (0.8-6.3) .13 1.9 (0.7-5.1) .18 2.6 (1.0-6.5) .04
FISH 1.6 (0.6-4.6) .34
uCyt+ 3.23 (1.2-8.7) .01
NMP22 3.1 (1.2-8.6) .01
Last tumor < vs. > 6 months 3.6 (1.5-8.9) .001 3.8 (1.6-9.6) .003 4.2 (1.7-11.0) .002 3.0 (1.2-7.9) .01
History of low/intermediate vs. high risk urothelial carcinoma 1.2 (0.5-2.9) .83 1.1 (0.5-2.7) .72 1.4 (0.5-3.5) .51 1.2 (0.5-3.2) .64
FISH = Fluorescence in situ hybridization, NMP22 = Nuclear matrix protein 22, uCyt+ = Immunocytology
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lysis (MA). In a study by van Rhjin et al., MA was able to
detect 75% of tumor recurrences. In the group of patients
with positive MA and negative cystoscopy, 55% experi-
enced recurrence within six months vs. 11.6% in patients
with negative MA [25]. Similar results were obtained by
van der Aa et al., who prospectitvely assessed the predict-
ive value of MA in a longitudinal analysis for 458 series
with persistent MA results. They observed, that patients
with persistent positive MA analysis had a 83% risk of re-
currence after two years vs. 22% in patients with persistent
negative MA analysis. Positive MA series preceded recur-
rences by one to 24 months [26].
Analysis of FGFR3 mutations in voided urine samples
of patients with history of FGFR3 mutant tumors was
performed in a study by Zuiverloon et al. They observed,
that that a single positive FGFR3 test was associated
with a three times higher risk of a recurrence. In pa-
tients with consecutive FGFR3-positive urine samples
the risk of developing a recurrence within 39 months
was 90% [27].
For immunocytology, no report exists so far on antici-
patory positive tests. In a study from Montreal including
109 patients during surveillance of BC, immunocytology
results were correlated with tumor presence within
12 months [28]. However, the study, which showed a
proportion of patients with tumor during 12 months of
76%, does not provide detailed information on when the
recurrences occurred and how immunocytology pre-
dicted recurrences in patients with a negative cystoscopy
at study inclusion. Similar to FISH, we observed no dif-
ference in recurrence free survival between patients with
negative cytology and positive or negative immunocytol-
ogy in our study. This might be due to a high percentage
of patients (68.4%) showing an overlap of results of cy-
tology and immunocytology.
Interestingly, NMP22 was the only marker being
strongly predictive for recurrence in cytology negative
patients. This might be explained by the different fea-
tures covered by both tests. In our study, it was the testwith the lowest concordance with cytology (43.0% of pa-
tients showed different results for cytology and NMP22).
Such a strong correlation with risk of recurrence has not
been observed in literature yet. However, the fact that
NMP22 might be a test offering more additional infor-
mation than other markers when used in combination
with cytology has also been observed before [28,29]. Be-
sides NMP22, other protein based urine markers have
been also investigated for their potential in predicting
recurrences in patients undergoing surveillance of
NMIBC. In a study by Sanchez-Carbayo et al, patients
under surveillance received serial testing for Urinary
Bladder Cancer test (UBC), CYFRA-21-1 and NMP22.
In the group of 65 patients with persistent negative
markers during the study, only four patients developed
recurrence within the one year follow-up of the study.
The authors concluded, that urinary markers should be
considered as adjuncts enabling individualized cystoscopy
intervals during NMIBC surveillance [30].
The present study is the first study addressing the
question, how combinations of multiple markers may
help to improve prediction of recurrence and progres-
sion when assessed at time of negative cystoscopy. Al-
though we observed that patients having all tests
positive in a 4-marker-combination are at higher risk for
recurrence than patients with less markers positive, the
identification of patients with low risk of recurrence and
progression was not improved significantly when using
four instead of two markers. When discussing urine
markers as potential tool to individualize cystoscopy in-
tervals during BC surveillance, patients and urologists
expect a high negative predictive value (NPV) for this
test with regards to prediction of recurrence and/or pro-
gression. Therefore, the use of more than two markers
has to be questioned in this context, as it does not seem
to improve the NPV compared to the 2-test-combina-
tions with high NPV. Furthermore, the use of multiple
markers is associated with a significant increase in costs.
The limitations of our study include the size and the
heterogeneity of the cohort. Although we controlled for
Todenhöfer et al. BMC Cancer  (2015) 15:155 Page 10 of 11this bias in multivariate analysis, the inclusion of pa-
tients with different intervals between last evidence of
tumor and urine marker testing might have influenced
the results. Furthermore, we cannot exclude that the re-
sults of the urine markers influenced cystoscopy inter-
vals as treating urologist were not blinded to the test
results. However, the inclusion of patients with a follow-
up of at least 24 months and the performance of tests
which took the presence of tumor within 24 months as
an endpoint (regardless of the time to recurrence) may
partially control for this bias. As only a part of the pa-
tients underwent mapping biopsies during cystoscopy, it
cannot be completely ruled out that carcinoma in situ
was present at time of initial cystoscopic assessment.
Moreover, the sensitivity of upper tract imaging for de-
tection of upper urinary tract urothelial carcinoma is
limited. To exclude presence of upper tract tumors, a
ureteroscopic assessment of all patients would have been
necessary. However, none of the patients presented clin-
ical symptoms of upper tract urothelial carcinoma within
the follow-up of two years.Conclusions
The present study shows that patients with positive cy-
tology, uCyt+, FISH or NMP22 test at time of negative
cystoscopy exhibit a shorter time to disease recurrence
and progression. For the first time, NMP22 is identified
as a predictor of recurrence and progression in patients
with negative cystoscopy and cytology. Negative combi-
nations of NMP22 and a second urine marker are asso-
ciated with a low risk of recurrence within two years.
The endoscopic follow-up regimen may be therefore
attenuated in patients with persistent negative results of
these markers.
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